Denosumab Dosing and Administration
The recommended dose of denosumab is 60 mg administered subcutaneously every 6 months for osteoporosis, or 120 mg subcutaneously every 4 weeks for bone metastases from solid tumors. 1, 2
Osteoporosis Dosing
For postmenopausal osteoporosis, men with osteoporosis, and glucocorticoid-induced osteoporosis:
- Dose: 60 mg subcutaneous injection
- Frequency: Every 6 months (once every 6 months)
- Administration site: Upper arm, upper thigh, or abdomen 2
The 2019 Endocrine Society guidelines strongly recommend this regimen for postmenopausal women at high risk for osteoporotic fractures 1. The AACE 2020 guidelines similarly endorse 60 mg subcutaneously every 6 months 3.
Critical Timing Considerations
Strict adherence to the 6-month dosing schedule is essential. The effects of denosumab on bone remodeling reverse after 6 months if the drug is not taken on schedule 1. Bone turnover markers begin to rise as serum denosumab levels diminish toward the end of each 6-month interval 2. Drug holidays or treatment interruptions are NOT recommended with denosumab 1.
Dosing intervals exceeding 210 days (7 months) constitute non-adherence and place patients at increased risk of rebound bone resorption and vertebral fractures 4.
Bone Metastases Dosing
For prevention of skeletal-related events in patients with bone metastases from solid tumors:
This higher dose and more frequent schedule is specifically for oncology indications. The NCCN 2020 guidelines support this regimen for women with metastatic breast cancer to bone 5.
Adjuvant Breast Cancer Dosing
For postmenopausal women with early breast cancer receiving aromatase inhibitors:
The ABCSG-18 trial demonstrated that this regimen reduces clinical fractures and improves disease-free survival in this population 7, 8.
Essential Co-Administration Requirements
All patients receiving denosumab must take calcium and vitamin D supplementation to minimize the risk of hypocalcemia 1, 3, 7:
- Calcium: 1,200-1,500 mg daily
- Vitamin D: 400-800 IU daily (some sources recommend up to 1,000 IU)
Denosumab is contraindicated in patients with pre-existing hypocalcemia 3, 2.
Critical Safety Warnings
Rebound Effect Upon Discontinuation
If denosumab must be discontinued, patients MUST receive subsequent antiresorptive therapy (bisphosphonate, hormone therapy, or SERM) to prevent rebound bone turnover 1. After stopping denosumab, bone resorption markers increase to 40-60% above pretreatment values, creating a window of vulnerability for multiple vertebral fractures 3, 9.
Zoledronic acid is recommended as bridging therapy if denosumab is stopped for more than 6 months 9.
Dental Precautions
Patients should have a dental evaluation and complete any necessary invasive dental procedures before initiating denosumab 7, 9. Good oral hygiene must be maintained throughout treatment to minimize osteonecrosis of the jaw risk 7, 10.
Duration of Therapy
Fracture risk should be reassessed after 5-10 years of treatment. Patients who remain at high risk should either continue denosumab or switch to other osteoporosis therapies 1. Unlike bisphosphonates, denosumab does not have residual skeletal effects, so continuous treatment is typically required for ongoing benefit 11.
The FREEDOM Extension study demonstrated continued low fracture rates with denosumab treatment for up to 10 years 1.